US20120303134A1 - Stent with soluble bladder retention member - Google Patents
Stent with soluble bladder retention member Download PDFInfo
- Publication number
- US20120303134A1 US20120303134A1 US13/559,229 US201213559229A US2012303134A1 US 20120303134 A1 US20120303134 A1 US 20120303134A1 US 201213559229 A US201213559229 A US 201213559229A US 2012303134 A1 US2012303134 A1 US 2012303134A1
- Authority
- US
- United States
- Prior art keywords
- ureteral stent
- end portion
- dissolving
- patient
- proximal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010046555 Urinary retention Diseases 0.000 title description 4
- 239000000463 material Substances 0.000 claims abstract description 105
- 230000014759 maintenance of location Effects 0.000 claims abstract description 28
- 210000001635 urinary tract Anatomy 0.000 claims abstract description 27
- 210000001124 body fluid Anatomy 0.000 claims abstract description 26
- 210000003734 kidney Anatomy 0.000 claims description 15
- 210000000626 ureter Anatomy 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 4
- 238000010586 diagram Methods 0.000 description 19
- 238000004090 dissolution Methods 0.000 description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/008—Implant devices for drainage of body fluids from one part of the body to another pre-shaped, for use in the urethral or ureteral tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2002/048—Ureters
Definitions
- the disclosed invention relates generally to a medical device, and in particular, to a ureteral stent with a dissolving portion.
- ureteral stents are typically placed within a urinary tract of a patient such that one end portion of the ureteral stent is located in a kidney of the patient and another end portion of the ureteral stent is located in either a bladder or a ureter of the patient.
- Known ureteral stents are typically positioned within the urinary tract of the patient by placing a guidewire within the patient, sliding the ureteral stent on the guidewire, and then forcing the ureteral stent along the guidewire into a desired position within the patient using a push rod. Such ureteral stents are often removed from the patient by pulling the ureteral stent from the urinary tract of the patient.
- Some known ureteral stents include a retention member at a kidney end portion of the ureteral stent and a retention member at a bladder end portion of the ureteral stent.
- the retention member of the bladder end portion of the ureteral stent is configured to be placed within the bladder to help prevent migration of the ureteral stent upwardly toward the kidney.
- the retention member of the kidney end portion is configured to be placed within the kidney to help prevent migration of the ureteral stent downwardly toward the bladder.
- ureteral stents often cause pain and discomfort to the patient once the ureteral stents are positioned within the body.
- the retention member of the bladder end portion can irritate sensitive regions in the bladder such as the trigone region and/or intramural tunnel.
- a ureteral stent includes an elongate member that is configured to be disposed within a urinary tract of a patient to convey urine from a first portion of the urinary tract of the patient to a second portion of the urinary tract of the patient.
- the elongate member has a distal end portion, a proximal end portion, and a medial portion disposed between the distal end portion and the proximal end portion.
- the distal end portion includes a retention member configured to help retain at least a portion of the elongate member within a kidney of the patient and the proximal end portion includes a retention member configured to help retain at least a portion of the elongate member within a bladder of the patient.
- the proximal end portion of the elongate member includes a dissolving portion configured to dissolve in response to being exposed to a bodily fluid for a period of time.
- the elongate member also has a non-dissolving portion that includes the entire retention member of the distal end portion and is substantially stable in the bodily fluid of the urinary tract of the patient.
- the retention member of the distal end portion is constructed of a stent material that is substantially stable in the bodily fluid of the urinary tract of the patient.
- the proximal end portion includes a dissolving portion that is configured to dissolve in response to being exposed to a bodily fluid for a period of time and a non-dissolving portion that is substantially stable in the bodily fluid of the urinary tract of the patient.
- FIG. 1 is a schematic diagram that illustrates a ureteral stent, according to an embodiment of the invention, disposed within a urinary tract of a patient.
- FIG. 2 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention, disposed within a urinary tract of a patient.
- FIG. 3A is a schematic diagram of a side cross-sectional view of a ureteral stent, according to an embodiment of the invention, before a dissolving portion dissolves.
- FIG. 3B is a schematic diagram of a side cross-sectional view of the ureteral stent of FIG. 3A after the dissolving portion has dissolved.
- FIG. 4 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention.
- FIG. 5A is a schematic diagram of a side cross-sectional view of a ureteral stent, according to an embodiment of the invention, before a dissolving material dissolves.
- FIG. 5B is a schematic diagram of a side cross-sectional view of the ureteral stent of FIG. 5A after the dissolving material has dissolved.
- FIG. 6 is a schematic diagram of a side view of a proximal end portion and a medial portion of a ureteral stent, according to an embodiment of the invention.
- FIG. 7 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention.
- Ureteral stents having at least a portion of the ureteral stent constructed of a material that dissolves (e.g., soluble) after being exposed to a bodily fluid for a period of time are disclosed herein.
- the proximal end portion is configured to dissolve to substantially reduce and/or minimize irritation of sensitive regions in a bladder of a patient after the ureteral stent has been inserted.
- a distal end of the ureteral stent in contrast, is constructed of a material that is formulated to be substantially stable in the bodily fluid of the patient.
- at least a portion of a medial portion of the ureteral stent is also constructed with one or more dissolving materials.
- the proximal portion and/or the medial portion of the ureteral stent are constructed using various combinations of dissolving and/or non-dissolving materials.
- FIG. 1 is a schematic diagram that illustrates a ureteral stent 100 , according to an embodiment of the invention, disposed within a urinary tract of a patient.
- the ureteral stent 100 is positioned within a patient such that it extends from the kidney K, through the ureter U, and to the bladder B.
- the ureteral stent 100 is configured to facilitate the movement of fluid within a urinary tract of a patient, for example, from the kidney K to the bladder B via the ureter U.
- the ureteral stent 100 includes an elongate member 102 having a distal end portion 104 , a proximal end portion 106 , and a medial portion 108 extending between the distal end portion 104 and the proximal end portion 106 .
- the proximal end portion 106 includes a retention member 110 .
- the distal end portion 104 includes a retention member 112 .
- the retention member 110 of the proximal end portion 106 of the ureteral stent 100 is configured to be placed within the bladder B to help prevent migration of the ureteral stent 100 upwardly toward the kidney K.
- the retention member 112 of the distal end portion 104 is configured to be placed within the kidney K to help prevent migration of the ureteral stent 100 downwardly toward the bladder B.
- the retention members 110 and 112 are configured to help retain the ureteral stent 100 in place within the urinary tract of the patient.
- the retention members 110 and 112 may be configured in a variety of different shapes and sizes, such as a loop, a ⁇ '1′′ hook, a pig tail, a planar coil, and/or a malecot.
- the ureteral stent 100 includes a side wall 122 .
- the side wall 122 defines a lumen 124 .
- the lumen 124 extends from the distal end portion 104 to the proximal end portion 106 of the ureteral stent 100 .
- the lumen 124 only extends through a portion of the ureteral stent 100 .
- the ureteral stent 100 does not include a side wall 122 that defines a lumen 124 .
- At least a portion of the proximal end portion 106 of the ureteral stent 100 , and in some embodiments a portion of the medial portion 108 , are constructed of at least one dissolving material that is formulated to dissolve (e.g., soluble) in a bodily fluid after being inserted into the urinary tract of the patient.
- the dissolving material is configured to dissolve in a bodily fluid such as water, urine, mucous, etc. within hours of being placed in a specified location.
- the mixture of the bodily fluid and the dissolved and/or partially dissolved materials separated from the ureteral stent 100 can be voided from the bladder B of the patient.
- the dissolving material can be, for example, klucel (Hydroxypropylcellulose) or a different material configured to have, for example, a specified dissolution rate, length, biocompatibility, and/or level of rigidity.
- the proximal end portion 106 (including the retention member 110 ) is configured to dissolve so that the proximal end portion 106 does not irritate sensitive regions within the bladder B (e.g., trigone region). Because the tendency for the ureteral stent 100 to migrate antegrade or upwards into the kidney K is low compared with the tendency towards downward or retrograde migration into the bladder B due to gravity and downward peristalsis in the ureter, dissolution of the proximal end portion 106 after placement of the ureteral stent 100 can be beneficial. In other words, irritation of sensitive regions within the bladder B by the ureteral stent 100 and risk of undesirable movement of the ureteral stent 100 can be simultaneously reduced and/or minimized.
- the bladder B e.g., trigone region
- the ureteral stent 100 also includes a non-dissolving portion.
- the distal end portion 104 of the ureteral stent 100 in contrast to the proximal end portion 106 , is constructed of a stent material that is substantially stable in a bodily fluid of the patient (also can be referred to as non-dissolving).
- the non-dissolving portion of the ureteral stent 100 remains in the patient until the ureteral stent 100 is removed using a known or conventional ureteral stent extraction technique (e.g., removal using a tether).
- a portion of the medial portion 108 in addition to the distal end portion 104 , is constructed of a non-dissolving material.
- the non-dissolving material can be, for example, a polyolefin or a polyurethane.
- FIG. 2 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention, disposed within a urinary tract of a patient.
- the ureteral stent 200 includes an elongate member 202 having a distal end portion 204 , a proximal end portion 206 , and a medial portion 208 extending between the distal end portion 204 and the proximal end portion 206 .
- the proximal end portion 206 includes a retention member 210 .
- the distal end portion 204 includes a retention member 212 .
- the elongate member 202 of the ureteral stent 200 also includes a side wall 222 that defines a lumen 224 extending from the distal end portion 204 to the proximal end portion 206 of the ureteral stent 200 .
- the ureteral stent 200 is positioned within a patient such that it extends from a kidney K, through a ureter U, and into a trigone region 242 of a bladder B through an intramural tunnel 240 .
- the trigone region 242 is a smooth triangular region within the bladder B formed by the intramural tunnel 240 , a second intramural tunnel (not shown), and the internal urethral orifice (not shown).
- the distal end portion 204 , and, in some embodiments, a portion of the medial portion 208 is formed of a non-dissolving material that is substantially stable in the bodily fluid. In the illustrated embodiment, a distinct separation of the non-dissolving portion and the dissolving portion of the ureteral stent 200 is shown at 228 .
- the dissolving portion of the proximal end portion 206 can be sized so that irritation of the trigone region 242 and/or intramural tunnel 240 can be substantially reduced and/or minimized.
- the ureteral stent 200 can be configured so that after the dissolving portion of the proximal end portion 206 dissolves, the remaining portion of the ureteral stent 200 does not extend into the trigone region 242 or even into the intramural tunnel 240 .
- the ureteral stent is configured so that up to approximately one-third of the overall length of the ureteral stent dissolves. In some embodiments, the ureteral stent can be configured so that more than approximately one-third of the overall length of the ureteral stent dissolves.
- the rate of dissolution of the dissolving portion of the proximal end portion 206 can vary depending upon the type of material used as the dissolving portion and/or the geometry of the ureteral stent 200 .
- portions of the dissolving portion of the proximal end portion 206 can be configured to facilitate dissolution (e.g., porously configured structures, thin portions).
- the mixture of bodily fluids and the dissolved material from the ureteral stent 200 can be voided from the bladder B of the patient.
- Partially dissolved portions of the proximal end portion 206 that have been dissolved away and/or separated from the ureteral stent 200 in some embodiments, can also be naturally voided from the bladder B of the patient.
- FIGS. 3A and 3B are schematic diagrams of side cross-sectional views of a ureteral stent 300 at two different times.
- the difference(s) in FIGS. 3A and 3B illustrate a temporal change in the structure of the ureteral stent 300 as a result of the dissolution of a dissolving portion 350 of the ureteral stent 300 .
- FIG. 3A is a schematic diagram of a side cross-sectional view of the ureteral stent 300 before the dissolving portion 350 has dissolved.
- FIG. 3B is a schematic diagram of a side cross-sectional view of the ureteral stent of FIG. 3A after the dissolving portion 350 has dissolved, leaving a non-dissolving portion 360 .
- the ureteral stent 300 includes an elongate member 318 having a distal end portion 312 , a proximal end portion 314 , and a medial portion 316 extending between the distal end portion 312 and the proximal end portion 314 .
- the ureteral stent 300 also includes a side wall 322 that defines a lumen 324 extending from the distal end portion 314 to the proximal end portion 312 of the ureteral stent 300 .
- the proximal end portion 314 includes a retention member 334 and the distal end portion 312 includes a retention member 332 .
- a distinct separation of the dissolving portion 350 and the non-dissolving portion 360 of the ureteral stent 300 is shown at 320 .
- the separation at 320 is shown as a straight line in this embodiment, in some embodiments, the non-dissolving portion 360 and dissolving portion 350 can overlap, meet in an interlocking fashion, and so forth.
- the ureteral stent 300 also includes a tether 370 that can be used for removing the non-dissolving portion 360 of the ureteral stent 300 .
- FIG. 3B illustrates the non-dissolving portion 360 of the ureteral stent 300 that remains after the dissolving portion 350 of the ureteral stent 300 has dissolved.
- the entire retention member 332 of the distal end portion 312 is formulated with the non-dissolving material.
- the dissolving portion 350 can be configured to dissolve within hours of being inserted into a patient. In other embodiments, the dissolving portion is configured to dissolve in more or less time. In some embodiments, the dissolving portion 350 dissolves slowly over a longer period of time.
- FIG. 4 is a schematic diagram of a side view of a ureteral stent 400 , according to an embodiment of the invention, that includes an elongate member 418 having a distal end portion 412 , a proximal end portion 414 , and a medial portion 416 .
- the distal end portion 412 is formulated with a non-dissolving material 430
- the proximal end portion 412 is formulated with a first dissolving material 440
- the medial portion 416 is formulated with a second dissolving material 450 .
- the first dissolving material 440 and the second dissolving material 450 can be configured to have any combination of, for example, dissolution rates, lengths, biocompatibility, and/or levels of rigidity.
- the ureteral stent 400 is constructed with multiple types of dissolving and/or non-dissolving materials.
- FIGS. 5A and 5B are schematic diagrams of side cross-sectional views of a ureteral stent 500 at two different times.
- the difference(s) between FIGS. 5A and 5B illustrate a temporal change in the structure of the ureteral stent 500 as a result of the dissolution of a portion of the ureteral stent 500 .
- the ureteral stent 500 is configured with a soft non-dissolving material 520 (e.g., ultra-soft), a dissolving material 530 , and a non-dissolving material 550 .
- the dissolving material 530 and the non-dissolving material 550 are relatively rigid compared with the soft non-dissolving material 520 .
- FIG. 5A is a side cross-sectional view of the ureteral stent 500 before the dissolving material 530 has dissolved.
- FIG. 5B is a side cross-sectional view of the ureteral stent 500 of FIG. 5A after the dissolving material 530 has dissolved.
- the ureteral stent 500 shown in FIGS. 5A and 5B is configured such that the ureteral stent 500 is relatively rigid when being inserted into a urinary tract of a patient to facilitate placement of the ureteral stent 500 .
- the ureteral stent 500 is also configured so that after being exposed for a period of time, the relatively rigid dissolving material 530 dissolves, leaving the soft non-dissolving material 520 (rather than the relatively rigid material) in sensitive areas within the urinary tract of the patient (e.g., intramural tunnel, trigone region).
- Patient comfort can be increased by substantially reducing and/or minimizing exposure of the sensitive areas within the urinary tract of the patient to the relatively rigid materials of the ureteral stent 500 (e.g., through dissolution) that facilitate placement.
- FIGS. 5A and 5B show a proximal end portion 514 and a medial portion 516 of the ureteral stent 500 .
- the ureteral stent 500 also includes a distal end portion that is not shown in FIGS. 5A or 5 B.
- the proximal end portion 514 and a portion of the medial portion 516 of the ureteral stent 500 are constructed with the dissolving material 530 that is interior to the soft nondissolving material 520 (e.g., a soft and/or non-expanding material that is substantially stable in a urinary tract of a patient).
- the soft nondissolving material 520 e.g., a soft and/or non-expanding material that is substantially stable in a urinary tract of a patient.
- a portion of the medial portion 516 is constructed of the non-dissolving material 550 that is relatively rigid compared with the soft nondissolving material 520 .
- the dissolving material 530 and the non-dissolving material 530 meet at 560 and form side walls that define a lumen 540 .
- the soft non-dissolving material 520 is coupled with the non-dissolving material 550 as shown in FIGS. 5A and 5B .
- FIG. 5B is a schematic diagram that illustrates the soft non-dissolving material 520 and the non-dissolving material 550 after the dissolving material 530 has dissolved in response to being exposed to a bodily fluid of a patient for a period of the time.
- the lumen 540 after the dissolution of the dissolving material 530 , is defined by the soft non-dissolving material 520 and the non-dissolving material 550 .
- the ureteral stent 500 is configured so that when the dissolving material 530 dissolves and the ureteral stent 500 is in place within the patient, only the soft non-dissolving material 520 can come in contact with the most sensitive areas within the urinary tract of the patient such as the trigone region and/or intramural tunnel.
- FIG. 5A shows that the soft non-dissolving material 520 and the dissolving material 530 are coextensive, in some embodiments, the two materials 520 and 530 are not coextensive (e.g., different lengths).
- the portions of the ureteral stent 500 that are configured with the soft non-dissolving material 520 , the dissolving material 530 , and the non-dissolving material 550 can vary.
- only a retention member portion of the proximal end portion 514 can be formulated with the soft dissolving material 520 and the dissolving material 530 .
- portions or all of the soft dissolving material 520 can be exterior to the dissolving material 530 .
- the soft dissolving material 520 can be coupled to the non-dissolving material 550 in a variety of configurations (e.g., on an interior portion of the non-dissolving material 550 ).
- the ureteral stent 500 can be formulated with multiple types and/or combinations of soft and/or rigid materials that are nondissolving and/or dissolving.
- the proximal end portion 514 and/or a portion of the medial portion 516 can be formulated with a soft dissolving material that dissolves at a slower rate than the dissolving material.
- FIG. 6 is a schematic diagram of a side view of a proximal end portion 614 and a medial portion 616 of a ureteral stent 600 that is formulated with an ultra-soft non-dissolving material 620 that is exterior to a rigid dissolving material 630 , according to an embodiment of the invention.
- the medial portion 616 is formulated with a nondissolving material 650 that is rigid compared with the ultra-soft non-dissolving material 620 .
- FIG. 6 illustrates the dissolving material 630 and the non-dissolving material 650 meet at 640 .
- the ultra-soft non-dissolving material 620 is perforated to promote the dissolution of the dissolving material 630 after the ureteral stent 600 is exposed to a bodily fluid within a urinary tract of a patient.
- the ultra-soft non-dissolving material 620 is perforated with circles, the type of perforation can vary (e.g., squares, different sizes of circles, different patterns, etc.).
- the dissolving material 630 and/or nondissolving material 650 are also perforated. In some embodiments, only the dissolving material 630 is perforated.
- FIG. 7 is a schematic diagram of a side view of a ureteral stent 700 that includes an elongate member 718 that has a distal end portion 712 , a proximal end portion 714 , and a medial portion 716 , according to an embodiment of the invention.
- the distal end portion 712 is formulated with a non-dissolving material 720 .
- the proximal end portion 714 and a portion of the medial portion 716 are formulated with small sections of alternating non-dissolving 720 and dissolving 730 materials.
- the sections can be various shapes, patterns, and/or sizes.
- the non-dissolving 720 and dissolving 730 can be configured in an interlocking fashion.
- the dissolving material 730 dissolves and leaves the distal end portion 712 that is constructed of a nondissolving material 720 . Also, after the dissolving material 730 dissolves, the small sections of non-dissolving material 720 that are separated from the ureteral stent 700 can be voided from the patient.
- the non-dissolving portions 720 can be sized appropriately for voiding.
- multiple types of dissolving material are used as the dissolving material 730 . For example, a dissolving portion can be formulated with a first type of dissolving material and another dissolving portion can be formulated using a second type of dissolving material.
- the present invention provides a ureteral stent having at least a portion of a proximal end of the ureteral stent constructed with a material that dissolves after being exposed to a bodily fluid for a period of time.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Prostheses (AREA)
Abstract
Ureteral stents having at least a portion of a proximal end of the ureteral stent constructed with a material that dissolves after being exposed to a bodily fluid for a period of time are disclosed herein. At least a portion of the proximal end portion of the elongate member includes a dissolving portion configured to dissolve in response to being exposed to a bodily fluid for a period of time. The elongate member also includes a non-dissolving portion that includes the entire retention member of the distal end portion and is substantially stable in the bodily fluid of the urinary tract of the patient. In some embodiments, a medial portion of the ureteral stent is also constructed with one or more dissolving materials. In some implementations, the proximal and/or the medial portions of the ureteral stent are constructed using various combinations of dissolving and non-dissolving materials.
Description
- This application is a continuation of U.S. patent application Ser. No. 12/731,836, filed Mar. 25, 2010, entitled “STENT WITH SOLUBLE BLADDER RETENTION MEMBER,” which, in turn, is a continuation of U.S. patent application Ser. No. 11/855,274, filed Sep. 14, 2007, entitled “STENT WITH SOLUBLE BLADDER RETENTION MEMBER,” which, in turn, claims priority to U.S. Patent Application Ser. No. 60/826,642, filed Sep. 22, 2006, entitled “STENT WITH SOLUBLE BLADDER RETENTION MEMBER”, all of which are incorporated by reference herein in their entirety.
- The disclosed invention relates generally to a medical device, and in particular, to a ureteral stent with a dissolving portion.
- Known ureteral stents are typically placed within a urinary tract of a patient such that one end portion of the ureteral stent is located in a kidney of the patient and another end portion of the ureteral stent is located in either a bladder or a ureter of the patient. Known ureteral stents are typically positioned within the urinary tract of the patient by placing a guidewire within the patient, sliding the ureteral stent on the guidewire, and then forcing the ureteral stent along the guidewire into a desired position within the patient using a push rod. Such ureteral stents are often removed from the patient by pulling the ureteral stent from the urinary tract of the patient.
- Some known ureteral stents include a retention member at a kidney end portion of the ureteral stent and a retention member at a bladder end portion of the ureteral stent. The retention member of the bladder end portion of the ureteral stent is configured to be placed within the bladder to help prevent migration of the ureteral stent upwardly toward the kidney. Similarly, the retention member of the kidney end portion is configured to be placed within the kidney to help prevent migration of the ureteral stent downwardly toward the bladder.
- Known ureteral stents often cause pain and discomfort to the patient once the ureteral stents are positioned within the body. In particular, the retention member of the bladder end portion can irritate sensitive regions in the bladder such as the trigone region and/or intramural tunnel. Thus, a need exists for a ureteral stent that substantially reduces and/or minimizes irritation of sensitive regions of a urinary tract of a patient.
- A ureteral stent includes an elongate member that is configured to be disposed within a urinary tract of a patient to convey urine from a first portion of the urinary tract of the patient to a second portion of the urinary tract of the patient. The elongate member has a distal end portion, a proximal end portion, and a medial portion disposed between the distal end portion and the proximal end portion. The distal end portion includes a retention member configured to help retain at least a portion of the elongate member within a kidney of the patient and the proximal end portion includes a retention member configured to help retain at least a portion of the elongate member within a bladder of the patient.
- In some embodiments, the proximal end portion of the elongate member includes a dissolving portion configured to dissolve in response to being exposed to a bodily fluid for a period of time. The elongate member also has a non-dissolving portion that includes the entire retention member of the distal end portion and is substantially stable in the bodily fluid of the urinary tract of the patient.
- In another embodiment, the retention member of the distal end portion is constructed of a stent material that is substantially stable in the bodily fluid of the urinary tract of the patient. The proximal end portion includes a dissolving portion that is configured to dissolve in response to being exposed to a bodily fluid for a period of time and a non-dissolving portion that is substantially stable in the bodily fluid of the urinary tract of the patient.
- The present invention is described with reference to the accompanying drawings. In the drawings, identical or like reference numbers indicate identical or functionally similar elements.
-
FIG. 1 is a schematic diagram that illustrates a ureteral stent, according to an embodiment of the invention, disposed within a urinary tract of a patient. -
FIG. 2 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention, disposed within a urinary tract of a patient. -
FIG. 3A is a schematic diagram of a side cross-sectional view of a ureteral stent, according to an embodiment of the invention, before a dissolving portion dissolves. -
FIG. 3B is a schematic diagram of a side cross-sectional view of the ureteral stent ofFIG. 3A after the dissolving portion has dissolved. -
FIG. 4 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention. -
FIG. 5A is a schematic diagram of a side cross-sectional view of a ureteral stent, according to an embodiment of the invention, before a dissolving material dissolves. -
FIG. 5B is a schematic diagram of a side cross-sectional view of the ureteral stent ofFIG. 5A after the dissolving material has dissolved. -
FIG. 6 is a schematic diagram of a side view of a proximal end portion and a medial portion of a ureteral stent, according to an embodiment of the invention. -
FIG. 7 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention. - Ureteral stents having at least a portion of the ureteral stent constructed of a material that dissolves (e.g., soluble) after being exposed to a bodily fluid for a period of time are disclosed herein. Specifically, in one embodiment, the proximal end portion is configured to dissolve to substantially reduce and/or minimize irritation of sensitive regions in a bladder of a patient after the ureteral stent has been inserted. A distal end of the ureteral stent, in contrast, is constructed of a material that is formulated to be substantially stable in the bodily fluid of the patient. In some embodiments, at least a portion of a medial portion of the ureteral stent is also constructed with one or more dissolving materials. In other embodiments, the proximal portion and/or the medial portion of the ureteral stent are constructed using various combinations of dissolving and/or non-dissolving materials.
-
FIG. 1 is a schematic diagram that illustrates aureteral stent 100, according to an embodiment of the invention, disposed within a urinary tract of a patient. Theureteral stent 100 is positioned within a patient such that it extends from the kidney K, through the ureter U, and to the bladder B. Theureteral stent 100 is configured to facilitate the movement of fluid within a urinary tract of a patient, for example, from the kidney K to the bladder B via the ureter U. - The
ureteral stent 100 includes anelongate member 102 having adistal end portion 104, aproximal end portion 106, and amedial portion 108 extending between thedistal end portion 104 and theproximal end portion 106. Theproximal end portion 106 includes aretention member 110. Similarly, thedistal end portion 104 includes aretention member 112. - The
retention member 110 of theproximal end portion 106 of theureteral stent 100 is configured to be placed within the bladder B to help prevent migration of theureteral stent 100 upwardly toward the kidney K. Similarly, theretention member 112 of thedistal end portion 104 is configured to be placed within the kidney K to help prevent migration of theureteral stent 100 downwardly toward the bladder B. Accordingly, theretention members ureteral stent 100 in place within the urinary tract of the patient. Theretention members - The
ureteral stent 100 includes aside wall 122. In one embodiment theside wall 122 defines alumen 124. Thelumen 124 extends from thedistal end portion 104 to theproximal end portion 106 of theureteral stent 100. In some embodiments, thelumen 124 only extends through a portion of theureteral stent 100. In other embodiments, theureteral stent 100 does not include aside wall 122 that defines alumen 124. - At least a portion of the
proximal end portion 106 of theureteral stent 100, and in some embodiments a portion of themedial portion 108, are constructed of at least one dissolving material that is formulated to dissolve (e.g., soluble) in a bodily fluid after being inserted into the urinary tract of the patient. The dissolving material is configured to dissolve in a bodily fluid such as water, urine, mucous, etc. within hours of being placed in a specified location. After the dissolving portions of theproximal end portion 106 and/or themedial portion 108 have dissolved in the bodily fluid, the mixture of the bodily fluid and the dissolved and/or partially dissolved materials separated from theureteral stent 100 can be voided from the bladder B of the patient. The dissolving material can be, for example, klucel (Hydroxypropylcellulose) or a different material configured to have, for example, a specified dissolution rate, length, biocompatibility, and/or level of rigidity. - The proximal end portion 106 (including the retention member 110) is configured to dissolve so that the
proximal end portion 106 does not irritate sensitive regions within the bladder B (e.g., trigone region). Because the tendency for theureteral stent 100 to migrate antegrade or upwards into the kidney K is low compared with the tendency towards downward or retrograde migration into the bladder B due to gravity and downward peristalsis in the ureter, dissolution of theproximal end portion 106 after placement of theureteral stent 100 can be beneficial. In other words, irritation of sensitive regions within the bladder B by theureteral stent 100 and risk of undesirable movement of theureteral stent 100 can be simultaneously reduced and/or minimized. - The
ureteral stent 100 also includes a non-dissolving portion. Specifically, thedistal end portion 104 of theureteral stent 100, in contrast to theproximal end portion 106, is constructed of a stent material that is substantially stable in a bodily fluid of the patient (also can be referred to as non-dissolving). The non-dissolving portion of theureteral stent 100 remains in the patient until theureteral stent 100 is removed using a known or conventional ureteral stent extraction technique (e.g., removal using a tether). In some embodiments, a portion of themedial portion 108, in addition to thedistal end portion 104, is constructed of a non-dissolving material. The non-dissolving material can be, for example, a polyolefin or a polyurethane. -
FIG. 2 is a schematic diagram of a side view of a ureteral stent, according to an embodiment of the invention, disposed within a urinary tract of a patient. Theureteral stent 200 includes anelongate member 202 having adistal end portion 204, aproximal end portion 206, and amedial portion 208 extending between thedistal end portion 204 and theproximal end portion 206. Theproximal end portion 206 includes aretention member 210. Similarly, thedistal end portion 204 includes aretention member 212. Theelongate member 202 of theureteral stent 200 also includes aside wall 222 that defines alumen 224 extending from thedistal end portion 204 to theproximal end portion 206 of theureteral stent 200. Theureteral stent 200 is positioned within a patient such that it extends from a kidney K, through a ureter U, and into atrigone region 242 of a bladder B through anintramural tunnel 240. Thetrigone region 242 is a smooth triangular region within the bladder B formed by theintramural tunnel 240, a second intramural tunnel (not shown), and the internal urethral orifice (not shown). - At least a portion of the
proximal end portion 206, and in some embodiments a portion of themedial portion 208, is formulated to dissolve in a bodily fluid after being inserted into a patient. Thedistal end portion 204, and, in some embodiments, a portion of themedial portion 208, is formed of a non-dissolving material that is substantially stable in the bodily fluid. In the illustrated embodiment, a distinct separation of the non-dissolving portion and the dissolving portion of theureteral stent 200 is shown at 228. - The dissolving portion of the
proximal end portion 206 can be sized so that irritation of thetrigone region 242 and/orintramural tunnel 240 can be substantially reduced and/or minimized. For example, theureteral stent 200 can be configured so that after the dissolving portion of theproximal end portion 206 dissolves, the remaining portion of theureteral stent 200 does not extend into thetrigone region 242 or even into theintramural tunnel 240. In some embodiments, the ureteral stent is configured so that up to approximately one-third of the overall length of the ureteral stent dissolves. In some embodiments, the ureteral stent can be configured so that more than approximately one-third of the overall length of the ureteral stent dissolves. - The rate of dissolution of the dissolving portion of the
proximal end portion 206 can vary depending upon the type of material used as the dissolving portion and/or the geometry of theureteral stent 200. For example, portions of the dissolving portion of theproximal end portion 206 can be configured to facilitate dissolution (e.g., porously configured structures, thin portions). After the dissolving portion of theproximal end portion 206 has dissolved in bodily fluids, the mixture of bodily fluids and the dissolved material from theureteral stent 200 can be voided from the bladder B of the patient. Partially dissolved portions of theproximal end portion 206 that have been dissolved away and/or separated from theureteral stent 200, in some embodiments, can also be naturally voided from the bladder B of the patient. -
FIGS. 3A and 3B are schematic diagrams of side cross-sectional views of aureteral stent 300 at two different times. The difference(s) inFIGS. 3A and 3B illustrate a temporal change in the structure of theureteral stent 300 as a result of the dissolution of a dissolvingportion 350 of theureteral stent 300.FIG. 3A is a schematic diagram of a side cross-sectional view of theureteral stent 300 before the dissolvingportion 350 has dissolved.FIG. 3B is a schematic diagram of a side cross-sectional view of the ureteral stent ofFIG. 3A after the dissolvingportion 350 has dissolved, leaving anon-dissolving portion 360. - The
ureteral stent 300 includes anelongate member 318 having adistal end portion 312, aproximal end portion 314, and amedial portion 316 extending between thedistal end portion 312 and theproximal end portion 314. Theureteral stent 300 also includes aside wall 322 that defines alumen 324 extending from thedistal end portion 314 to theproximal end portion 312 of theureteral stent 300. Theproximal end portion 314 includes aretention member 334 and thedistal end portion 312 includes aretention member 332. In this embodiment, a distinct separation of the dissolvingportion 350 and thenon-dissolving portion 360 of theureteral stent 300 is shown at 320. Although the separation at 320 is shown as a straight line in this embodiment, in some embodiments, thenon-dissolving portion 360 and dissolvingportion 350 can overlap, meet in an interlocking fashion, and so forth. Theureteral stent 300 also includes atether 370 that can be used for removing thenon-dissolving portion 360 of theureteral stent 300. -
FIG. 3B illustrates thenon-dissolving portion 360 of theureteral stent 300 that remains after the dissolvingportion 350 of theureteral stent 300 has dissolved. Specifically, as best illustrated inFIG. 3B , theentire retention member 332 of thedistal end portion 312 is formulated with the non-dissolving material. The dissolvingportion 350 can be configured to dissolve within hours of being inserted into a patient. In other embodiments, the dissolving portion is configured to dissolve in more or less time. In some embodiments, the dissolvingportion 350 dissolves slowly over a longer period of time. -
FIG. 4 is a schematic diagram of a side view of aureteral stent 400, according to an embodiment of the invention, that includes anelongate member 418 having adistal end portion 412, aproximal end portion 414, and amedial portion 416. In this embodiment, thedistal end portion 412 is formulated with anon-dissolving material 430, theproximal end portion 412 is formulated with afirst dissolving material 440, and themedial portion 416 is formulated with asecond dissolving material 450. Thefirst dissolving material 440 and thesecond dissolving material 450 can be configured to have any combination of, for example, dissolution rates, lengths, biocompatibility, and/or levels of rigidity. In some embodiments, theureteral stent 400 is constructed with multiple types of dissolving and/or non-dissolving materials. -
FIGS. 5A and 5B are schematic diagrams of side cross-sectional views of aureteral stent 500 at two different times. The difference(s) betweenFIGS. 5A and 5B illustrate a temporal change in the structure of theureteral stent 500 as a result of the dissolution of a portion of theureteral stent 500. Theureteral stent 500 is configured with a soft non-dissolving material 520 (e.g., ultra-soft), a dissolvingmaterial 530, and anon-dissolving material 550. The dissolvingmaterial 530 and thenon-dissolving material 550 are relatively rigid compared with the softnon-dissolving material 520.FIG. 5A is a side cross-sectional view of theureteral stent 500 before the dissolvingmaterial 530 has dissolved.FIG. 5B is a side cross-sectional view of theureteral stent 500 ofFIG. 5A after the dissolvingmaterial 530 has dissolved. - The
ureteral stent 500 shown inFIGS. 5A and 5B is configured such that theureteral stent 500 is relatively rigid when being inserted into a urinary tract of a patient to facilitate placement of theureteral stent 500. Theureteral stent 500 is also configured so that after being exposed for a period of time, the relativelyrigid dissolving material 530 dissolves, leaving the soft non-dissolving material 520 (rather than the relatively rigid material) in sensitive areas within the urinary tract of the patient (e.g., intramural tunnel, trigone region). Patient comfort can be increased by substantially reducing and/or minimizing exposure of the sensitive areas within the urinary tract of the patient to the relatively rigid materials of the ureteral stent 500 (e.g., through dissolution) that facilitate placement. -
FIGS. 5A and 5B show aproximal end portion 514 and amedial portion 516 of theureteral stent 500. Theureteral stent 500 also includes a distal end portion that is not shown inFIGS. 5A or 5B. Specifically, as illustrated inFIG. 5A , theproximal end portion 514 and a portion of themedial portion 516 of theureteral stent 500 are constructed with the dissolvingmaterial 530 that is interior to the soft nondissolving material 520 (e.g., a soft and/or non-expanding material that is substantially stable in a urinary tract of a patient). A portion of themedial portion 516 is constructed of thenon-dissolving material 550 that is relatively rigid compared with thesoft nondissolving material 520. The dissolvingmaterial 530 and thenon-dissolving material 530 meet at 560 and form side walls that define alumen 540. In addition to being coupled with the dissolvingmaterial 530, the softnon-dissolving material 520 is coupled with thenon-dissolving material 550 as shown inFIGS. 5A and 5B . -
FIG. 5B is a schematic diagram that illustrates the softnon-dissolving material 520 and thenon-dissolving material 550 after the dissolvingmaterial 530 has dissolved in response to being exposed to a bodily fluid of a patient for a period of the time. Thelumen 540, after the dissolution of the dissolvingmaterial 530, is defined by the softnon-dissolving material 520 and thenon-dissolving material 550. Theureteral stent 500 is configured so that when the dissolvingmaterial 530 dissolves and theureteral stent 500 is in place within the patient, only the softnon-dissolving material 520 can come in contact with the most sensitive areas within the urinary tract of the patient such as the trigone region and/or intramural tunnel. - Although
FIG. 5A shows that the softnon-dissolving material 520 and the dissolvingmaterial 530 are coextensive, in some embodiments, the twomaterials ureteral stent 500 that are configured with the softnon-dissolving material 520, the dissolvingmaterial 530, and thenon-dissolving material 550 can vary. For example in some embodiments, only a retention member portion of theproximal end portion 514 can be formulated with thesoft dissolving material 520 and the dissolvingmaterial 530. In other embodiments, portions or all of thesoft dissolving material 520, rather than being interior to the dissolvingmaterial 530, can be exterior to the dissolvingmaterial 530. In these scenarios, thesoft dissolving material 520 can be coupled to thenon-dissolving material 550 in a variety of configurations (e.g., on an interior portion of the non-dissolving material 550). - Also, in some embodiments, the
ureteral stent 500 can be formulated with multiple types and/or combinations of soft and/or rigid materials that are nondissolving and/or dissolving. For example, rather than using a soft non-dissolving material, theproximal end portion 514 and/or a portion of themedial portion 516 can be formulated with a soft dissolving material that dissolves at a slower rate than the dissolving material. -
FIG. 6 is a schematic diagram of a side view of aproximal end portion 614 and amedial portion 616 of aureteral stent 600 that is formulated with an ultra-softnon-dissolving material 620 that is exterior to arigid dissolving material 630, according to an embodiment of the invention. Themedial portion 616 is formulated with anondissolving material 650 that is rigid compared with the ultra-softnon-dissolving material 620.FIG. 6 illustrates the dissolvingmaterial 630 and thenon-dissolving material 650 meet at 640. In this embodiment, the ultra-softnon-dissolving material 620 is perforated to promote the dissolution of the dissolvingmaterial 630 after theureteral stent 600 is exposed to a bodily fluid within a urinary tract of a patient. Although in this embodiment, the ultra-softnon-dissolving material 620 is perforated with circles, the type of perforation can vary (e.g., squares, different sizes of circles, different patterns, etc.). In some embodiments, the dissolvingmaterial 630 and/ornondissolving material 650 are also perforated. In some embodiments, only the dissolvingmaterial 630 is perforated. -
FIG. 7 is a schematic diagram of a side view of aureteral stent 700 that includes anelongate member 718 that has adistal end portion 712, aproximal end portion 714, and amedial portion 716, according to an embodiment of the invention. Thedistal end portion 712 is formulated with anon-dissolving material 720. Theproximal end portion 714 and a portion of themedial portion 716 are formulated with small sections of alternatingnon-dissolving 720 and dissolving 730 materials. In some embodiments, the sections can be various shapes, patterns, and/or sizes. For example, the non-dissolving 720 and dissolving 730 can be configured in an interlocking fashion. - After the
ureteral stent 700 is placed into a patient, the dissolvingmaterial 730 dissolves and leaves thedistal end portion 712 that is constructed of anondissolving material 720. Also, after the dissolvingmaterial 730 dissolves, the small sections ofnon-dissolving material 720 that are separated from theureteral stent 700 can be voided from the patient. Thenon-dissolving portions 720 can be sized appropriately for voiding. In some embodiments, multiple types of dissolving material are used as the dissolvingmaterial 730. For example, a dissolving portion can be formulated with a first type of dissolving material and another dissolving portion can be formulated using a second type of dissolving material. - In conclusion, the present invention provides a ureteral stent having at least a portion of a proximal end of the ureteral stent constructed with a material that dissolves after being exposed to a bodily fluid for a period of time. Those skilled in the art can readily recognize that numerous variations and substitutions may be made in the invention, its use and its configuration to achieve substantially the same results as achieved by the embodiments described herein. Many variations, modifications and alternative constructions fall within the scope and spirit of the disclosed invention as expressed in the claims.
Claims (18)
1. A ureteral stent, comprising:
a distal end portion configured to be disposed within at least one of a kidney and a ureter of a patient, the distal end portion including a non-dissolving portion, the non-dissolving portion being stable in a bodily fluid of a urinary tract of the patient;
a proximal end portion configured to be disposed within at least one of a ureter and a bladder of the patient, the proximal end portion including a dissolving portion, the dissolving portion being configured to dissolve in response to being exposed to the bodily fluid for a period of time; and
a tether coupled to the distal end portion and configured to help remove the distal end portion from the body of the patient.
2. The ureteral stent of claim 1 , wherein the distal end portion defines a lumen.
3. The ureteral stent of claim 1 , wherein the proximal end portion defines a lumen.
4. The ureteral stent of claim 1 , wherein the distal end portion defines a lumen and the proximal end portion defines a lumen, the lumen defined by the distal end portion being in fluid communication with the lumen defined by the proximal end portion.
5. The ureteral stent of claim 1 , wherein the proximal end portion defines a lumen and at least a portion of the tether is disposed within the lumen defined by the proximal end portion.
6. The ureteral stent of claim 1 , wherein the distal end portion includes a retention member configured to help retain a portion of the ureteral stent within a kidney of a patient, the proximal end portion includes a retention member configured to help retain a portion of the ureteral sent within a bladder of a patient.
7. The ureteral stent of claim 1 , wherein the distal end portion includes a curved retention member.
8. The ureteral stent of claim 1 , wherein the proximal end portion includes a curved retention member.
9. The ureteral stent of claim 1 , wherein a portion of the distal end portion overlaps a portion of the proximal end portion.
10. The ureteral stent of claim 1 , wherein a portion of the proximal end portion overlaps a portion of the distal end portion.
11. The ureteral stent of claim 1 , wherein the proximal end portion extends from and is coupled to the distal end portion.
12. A ureteral stent, comprising:
a first portion;
a second portion; and
a third portion,
the second portion is disposed between the first portion and the third portion, the first portion includes a non-dissolving material, the non-dissolving material being formulated to be stable in a bodily fluid of a urinary tract of a patient, the second portion includes a dissolving material, the dissolving material being formulated to dissolve in response to being exposed to the bodily fluid of the urinary tract of the patient, and the third portion includes a non-dissolving material.
13. The ureteral stent of claim 12 , wherein the third portion is configured to separate from the first portion in response to the second portion dissolving.
14. The ureteral stent of claim 12 , wherein the third portion is coupled to the first portion via the second portion.
15. The ureteral stent of claim 12 , wherein the first portion includes a retention member and is configured to be disposed in at least one of a kidney of a patient and a ureter of a patient.
16. The ureteral stent of claim 12 , wherein the first portion defines a lumen, the second portion defines a lumen, and the third portion defines a lumen.
17. The ureteral stent of claim 12 , wherein the first portion defines a lumen, the second portion defines a lumen, and the third portion defines a lumen, the lumen of the first portion being in fluid communication with the lumen of the second portion, the lumen of the second portion being in fluid communication with the lumen of the third portion.
18. The ureteral sent of claim 12 , further comprising:
a fourth portion; and
a fifth portion,
the fourth portion being disposed between the third portion and the fifth portion, the fourth portion including a dissolving material, the fifth portion including a non-dissolving portion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/559,229 US20120303134A1 (en) | 2006-09-22 | 2012-07-26 | Stent with soluble bladder retention member |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82664206P | 2006-09-22 | 2006-09-22 | |
US11/855,274 US7713308B2 (en) | 2006-09-22 | 2007-09-14 | Stent with soluble bladder retention member |
US12/731,836 US8246690B2 (en) | 2006-09-22 | 2010-03-25 | Stent with soluble bladder retention member |
US13/559,229 US20120303134A1 (en) | 2006-09-22 | 2012-07-26 | Stent with soluble bladder retention member |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/731,836 Continuation US8246690B2 (en) | 2006-09-22 | 2010-03-25 | Stent with soluble bladder retention member |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120303134A1 true US20120303134A1 (en) | 2012-11-29 |
Family
ID=38868246
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/855,274 Active 2027-11-10 US7713308B2 (en) | 2006-09-22 | 2007-09-14 | Stent with soluble bladder retention member |
US12/731,836 Active 2027-12-30 US8246690B2 (en) | 2006-09-22 | 2010-03-25 | Stent with soluble bladder retention member |
US13/559,229 Abandoned US20120303134A1 (en) | 2006-09-22 | 2012-07-26 | Stent with soluble bladder retention member |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/855,274 Active 2027-11-10 US7713308B2 (en) | 2006-09-22 | 2007-09-14 | Stent with soluble bladder retention member |
US12/731,836 Active 2027-12-30 US8246690B2 (en) | 2006-09-22 | 2010-03-25 | Stent with soluble bladder retention member |
Country Status (2)
Country | Link |
---|---|
US (3) | US7713308B2 (en) |
WO (1) | WO2008036711A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110196507A1 (en) * | 2001-04-02 | 2011-08-11 | Boston Scientific Scimed, Inc. | Medical stent and related methods |
US20110230950A1 (en) * | 2008-09-16 | 2011-09-22 | Tracey Knapp | Stent |
US9707383B2 (en) | 2012-12-19 | 2017-07-18 | Benoit VOGT | Ureteral stent and method for treating urological problems |
JP2021509829A (en) * | 2017-12-22 | 2021-04-08 | ポリ−メド インコーポレイテッド | Tubular implant with controlled biodegradation |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713308B2 (en) * | 2006-09-22 | 2010-05-11 | Boston Scientific Scimed, Inc. | Stent with soluble bladder retention member |
US8956419B2 (en) * | 2007-05-14 | 2015-02-17 | Boston Scientific Scimed, Inc. | Open lumen stent |
US20090171465A1 (en) * | 2007-12-28 | 2009-07-02 | Boston Scientific Scimed, Inc. | Polymeric Regions For Implantable Or Insertable Medical Devices |
US8192500B2 (en) | 2008-12-12 | 2012-06-05 | Boston Scientific Scimed, Inc. | Ureteral stent |
US8512272B2 (en) | 2008-12-22 | 2013-08-20 | Boston Scientific Scimed, Inc. | Ureteral stent |
US9789293B2 (en) * | 2010-06-24 | 2017-10-17 | Boston Scientific Scimed, Inc. | Stents with bladder retention members |
WO2012007053A1 (en) * | 2010-07-16 | 2012-01-19 | Ethicon Endo-Surgery, Inc. | A length adjustable catheter for directing biliopancreatic secretions |
WO2012163413A1 (en) * | 2011-05-31 | 2012-12-06 | Ethicon Endo-Surgery, Inc. | Catheter for directing biliopancreatic secretions |
US10857336B2 (en) * | 2012-05-19 | 2020-12-08 | Taris Biomedical Llc | Implantable urological device with improved retrieval feature |
EP2858710B1 (en) * | 2012-06-08 | 2020-10-07 | University Hospitals Health System Inc. | Ureteral stent for placement in a kidney and bladder |
WO2015120120A1 (en) * | 2014-02-07 | 2015-08-13 | Cook Medical Technologies Llc | Telescoping stent |
US9980831B2 (en) | 2015-01-30 | 2018-05-29 | FutureMatrix Interventional | Ureteral stent |
WO2017192145A1 (en) | 2016-05-06 | 2017-11-09 | University Hospitals Health Systems, Inc. | Ureteral stent |
CN117503421B (en) * | 2023-11-22 | 2024-07-30 | 香港大学深圳医院 | Ureteral stent convenient to get and put |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671795A (en) * | 1984-11-19 | 1987-06-09 | Mulchin William L | Permanent/retrievable ureteral catheter |
US4790810A (en) * | 1985-11-04 | 1988-12-13 | American Medical Systems, Inc. | Ureteral connector stent |
US4931037A (en) * | 1988-10-13 | 1990-06-05 | International Medical, Inc. | In-dwelling ureteral stent and injection stent assembly, and method of using same |
US6395021B1 (en) * | 1997-02-26 | 2002-05-28 | Applied Medical Resources Corporation | Ureteral stent system apparatus and method |
US6582472B2 (en) * | 1997-02-26 | 2003-06-24 | Applied Medical Resources Corporation | Kinetic stent |
US20030171708A1 (en) * | 2002-03-07 | 2003-09-11 | Joseph Segura | Ureteral stent |
US20030224033A1 (en) * | 2002-02-08 | 2003-12-04 | Jianmin Li | Implantable or insertable medical devices for controlled drug delivery |
US6676623B2 (en) * | 2001-05-04 | 2004-01-13 | Scimed Life Systems, Inc. | Drainage devices and methods |
US20040022824A1 (en) * | 2002-07-31 | 2004-02-05 | Scimed Life Systems, Inc. | Controlled drug delivery |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1250704B (en) | 1967-09-21 | |||
US662020A (en) * | 1899-05-09 | 1900-11-20 | Ver Elek Citaets Actiengesellschaft | Means for rapidly transmitting telegrams. |
FR2133083A5 (en) | 1971-04-07 | 1972-11-24 | Rhone Poulenc Sa | |
US3999551A (en) | 1975-01-07 | 1976-12-28 | Bio-Medical Research, Ltd. | Subcutaneous guide assembly |
FR2409747A1 (en) | 1977-11-28 | 1979-06-22 | Rey Pierre | NEW TOTAL OR PARTIAL URETERAL PROSTHESES |
US4212304A (en) | 1978-04-07 | 1980-07-15 | Medical Engineering Corp. | Uretheral catheter stent |
FI69351C (en) | 1979-01-22 | 1986-01-10 | Jan Axel Svensson | SLIDVENTIL- OCH KOPPLINGSAGGREGAT |
US4334327A (en) | 1979-12-21 | 1982-06-15 | University Of Utah | Ureteral prosthesis |
US4512770A (en) | 1983-01-27 | 1985-04-23 | The Kendall Company | Liquid drainage system with anti-reflux valve |
DE3339179A1 (en) | 1983-10-28 | 1985-05-09 | Felix 4370 Marl Beiring | Separating device for ureteral stents |
US4574806A (en) | 1984-10-01 | 1986-03-11 | Cordis Corporation | Tunnelling device for peripheral vascular reconstruction |
DE3525165A1 (en) | 1985-07-13 | 1987-01-15 | Braun Melsungen Ag | URETARY GUIDE CATHETER |
US4820262A (en) | 1985-12-12 | 1989-04-11 | Medical Engineering Corporation | Ureteral stent |
US4685905A (en) | 1986-02-20 | 1987-08-11 | Clinical Plastic Products | Implantable arterial catheter, especially multidose injection catheter |
DE8614013U1 (en) | 1986-05-23 | 1986-07-17 | Uromed Kurt Drews, 2000 Oststeinbek | Ureteral stent |
DE3741832A1 (en) | 1987-12-10 | 1989-06-22 | Hoene Eberhard | DYNAMIC HOOD VALVE INSERTED INNER URINE GUIDE RAIL TO PREVENT URINE RETURN FLOW IN THE UPPER URINE WAYS |
US5085629A (en) | 1988-10-06 | 1992-02-04 | Medical Engineering Corporation | Biodegradable stent |
US5049138A (en) | 1989-11-13 | 1991-09-17 | Boston Scientific Corporation | Catheter with dissolvable tip |
US5120317A (en) | 1991-03-14 | 1992-06-09 | Luther Medical Products, Inc. | Vascular/venous access device and method of utilizing and forming the same |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5464450A (en) | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
US5205830A (en) | 1991-11-12 | 1993-04-27 | Arrow International Investment Corporation | Catheter assembly |
US5599291A (en) * | 1993-01-04 | 1997-02-04 | Menlo Care, Inc. | Softening expanding ureteral stent |
US5964744A (en) * | 1993-01-04 | 1999-10-12 | Menlo Care, Inc. | Polymeric medical device systems having shape memory |
US5401257A (en) | 1993-04-27 | 1995-03-28 | Boston Scientific Corporation | Ureteral stents, drainage tubes and the like |
FI954565A0 (en) * | 1995-09-27 | 1995-09-27 | Biocon Oy | Biologically applied polymeric material to the implant and foil preparation |
US5814006A (en) | 1996-05-28 | 1998-09-29 | Planz; Konrad | Temporary stent in the urine path |
US20060025726A1 (en) * | 1996-06-04 | 2006-02-02 | Vance Products Incorporated, D/B/A Cook Urological Incorporated | Implantable medical device with pharmacologically active layer |
US6368356B1 (en) * | 1996-07-11 | 2002-04-09 | Scimed Life Systems, Inc. | Medical devices comprising hydrogel polymers having improved mechanical properties |
US8172897B2 (en) | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
US6284333B1 (en) | 1997-09-10 | 2001-09-04 | Scimed Life Systems, Inc. | Medical devices made from polymer blends containing low melting temperature liquid crystal polymers |
RU2215542C2 (en) | 1998-02-23 | 2003-11-10 | Массачусетс Инститьют Оф Текнолоджи | Biodecomposing polymers able recovery of form |
US6709465B2 (en) | 1999-03-18 | 2004-03-23 | Fossa Medical, Inc. | Radially expanding ureteral device |
US20030040800A1 (en) | 2000-04-26 | 2003-02-27 | Li Lehmann K. | Apparatus and method for replacing the nucleus pulposus of an intervertebral disc or for replacing an entire intervertebral disc |
US6913765B2 (en) | 2001-03-21 | 2005-07-05 | Scimed Life Systems, Inc. | Controlling resorption of bioresorbable medical implant material |
US6719804B2 (en) * | 2001-04-02 | 2004-04-13 | Scimed Life Systems, Inc. | Medical stent and related methods |
US6887215B2 (en) | 2001-06-01 | 2005-05-03 | Boston Scientific Scimed, Inc. | Compressible ureteral stent for comfort |
US6620202B2 (en) * | 2001-10-16 | 2003-09-16 | Scimed Life Systems, Inc. | Medical stent with variable coil and related methods |
US6676624B2 (en) | 2001-12-20 | 2004-01-13 | Scimed Life Systems, Inc. | Drainage devices and methods |
US7993390B2 (en) | 2002-02-08 | 2011-08-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US20030153972A1 (en) * | 2002-02-14 | 2003-08-14 | Michael Helmus | Biodegradable implantable or insertable medical devices with controlled change of physical properties leading to biomechanical compatibility |
US6908447B2 (en) | 2002-04-18 | 2005-06-21 | Scimed Life Systems, Inc. | Anti-reflux ureteral stents and methods |
EP3311759B1 (en) | 2002-04-18 | 2020-12-09 | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH | Shape memory polymeric sutures |
US7261734B2 (en) * | 2002-04-23 | 2007-08-28 | Boston Scientific Scimed, Inc. | Resorption-controllable medical implants |
WO2004032795A2 (en) | 2002-10-09 | 2004-04-22 | Fossa Medical, Inc. | Eccentric lumen stents |
US7044981B2 (en) | 2003-01-22 | 2006-05-16 | Boston Scientific Scimed, Inc. | Ureteral stent configured for improved patient comfort and aftercare |
EP1635734A2 (en) * | 2003-06-09 | 2006-03-22 | MacroPore Biosurgery, Inc. | Helical endoluminal stent and related methods |
US7713308B2 (en) | 2006-09-22 | 2010-05-11 | Boston Scientific Scimed, Inc. | Stent with soluble bladder retention member |
EP2197394B1 (en) * | 2007-08-31 | 2013-03-27 | Cook Medical Technologies LLC | Medical implant having improved drug eluting features |
-
2007
- 2007-09-14 US US11/855,274 patent/US7713308B2/en active Active
- 2007-09-19 WO PCT/US2007/078849 patent/WO2008036711A1/en active Application Filing
-
2010
- 2010-03-25 US US12/731,836 patent/US8246690B2/en active Active
-
2012
- 2012-07-26 US US13/559,229 patent/US20120303134A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671795A (en) * | 1984-11-19 | 1987-06-09 | Mulchin William L | Permanent/retrievable ureteral catheter |
US4790810A (en) * | 1985-11-04 | 1988-12-13 | American Medical Systems, Inc. | Ureteral connector stent |
US4931037A (en) * | 1988-10-13 | 1990-06-05 | International Medical, Inc. | In-dwelling ureteral stent and injection stent assembly, and method of using same |
US6395021B1 (en) * | 1997-02-26 | 2002-05-28 | Applied Medical Resources Corporation | Ureteral stent system apparatus and method |
US6582472B2 (en) * | 1997-02-26 | 2003-06-24 | Applied Medical Resources Corporation | Kinetic stent |
US6676623B2 (en) * | 2001-05-04 | 2004-01-13 | Scimed Life Systems, Inc. | Drainage devices and methods |
US20030224033A1 (en) * | 2002-02-08 | 2003-12-04 | Jianmin Li | Implantable or insertable medical devices for controlled drug delivery |
US20030171708A1 (en) * | 2002-03-07 | 2003-09-11 | Joseph Segura | Ureteral stent |
US20040022824A1 (en) * | 2002-07-31 | 2004-02-05 | Scimed Life Systems, Inc. | Controlled drug delivery |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110196507A1 (en) * | 2001-04-02 | 2011-08-11 | Boston Scientific Scimed, Inc. | Medical stent and related methods |
US20110230950A1 (en) * | 2008-09-16 | 2011-09-22 | Tracey Knapp | Stent |
US8764847B2 (en) * | 2008-09-16 | 2014-07-01 | C. R. Bard, Inc. | Stent |
US9707383B2 (en) | 2012-12-19 | 2017-07-18 | Benoit VOGT | Ureteral stent and method for treating urological problems |
JP2021509829A (en) * | 2017-12-22 | 2021-04-08 | ポリ−メド インコーポレイテッド | Tubular implant with controlled biodegradation |
US12016764B2 (en) * | 2017-12-22 | 2024-06-25 | Poly-Med, Inc. | Tubular implants with controlled biodegradation |
Also Published As
Publication number | Publication date |
---|---|
US20100179666A1 (en) | 2010-07-15 |
US8246690B2 (en) | 2012-08-21 |
US20080077250A1 (en) | 2008-03-27 |
US7713308B2 (en) | 2010-05-11 |
WO2008036711A1 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7713308B2 (en) | Stent with soluble bladder retention member | |
CA2447991C (en) | Draining bodily fluids with a stent | |
EP3129097B1 (en) | Ureteral stents | |
US5865815A (en) | Prostatic obstruction relief catheter | |
US4307723A (en) | Externally grooved ureteral stent | |
US6913625B2 (en) | Ureteral stent | |
US6524268B2 (en) | Combination ureteral infusion catheter/drainage stent | |
EP0808611B1 (en) | Anti-reflux ureteral stent | |
US6887215B2 (en) | Compressible ureteral stent for comfort | |
US7682401B2 (en) | Ureteral stent | |
US20150127115A1 (en) | Open lumen stent | |
US20030163204A1 (en) | Stent | |
JP2005312898A (en) | Improved stent | |
US8506647B2 (en) | System for maintaining body canal patency | |
JP2009538166A (en) | Prostate stent | |
US20210259863A1 (en) | Ureteral Stent and Related Methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMOS, RAYMOND G., JR.;REEL/FRAME:029220/0602 Effective date: 20070906 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |